Latest Healthcare News

Algorae Pharmaceuticals has broadened its commercial footprint in Australia and New Zealand through key licensing agreements, while advancing its AI-driven drug discovery platform and strengthening leadership.

CONNEQT Health has landed a significant Phase 2b clinical trial contract in the US, advancing its footprint in cardiovascular disease research with proprietary vascular assessment technology.

Memphasys has signed a pivotal supply agreement with Andro Diagnostics to distribute its Felix™ sperm separation system across over 200 IVF clinics in India, marking a major step in its new global go-direct commercial strategy.

Syntara Limited reports encouraging Phase 2a results for amsulostat in myelofibrosis, with significant symptom relief and spleen volume reduction sustained over 12 months, alongside new clinical trial initiations and a solid cash position.

Alcidion Group Limited has reported a robust start to FY26, posting $8.2 million in new sales and significantly improving its operating cash flow. The company reaffirms its guidance for positive EBITDA and cash flow for the full year.

EMVision Medical Devices has expanded its pivotal clinical trial sites, secured a $3 million government grant, and raised $14 million through placement and share purchase plan, positioning itself strongly for upcoming regulatory submissions and commercialisation.

Clarity Pharmaceuticals has responded to ASX queries clarifying the timing and materiality of its SAR-bisFAP data presentation, denying the information was price sensitive despite a notable share price rise.

Cambium Bio has locked in a significant R&D tax rebate and forged three strategic partnerships, underpinning its Phase 3 clinical trials for its lead ophthalmology biologic. The company’s recent capital raise further strengthens its runway as it prepares for pivotal trial milestones.

Cann Group Limited announces a transformative $9 million capital raise alongside a major debt restructure, positioning the medicinal cannabis pioneer for profitability in FY26.

Cann Group Limited has executed a transformative debt restructure, reducing its $70 million debt by 81% and raising $9 million in fresh capital, setting the stage for a positive EBITDA turnaround in FY26.

Talius Group has raised $4 million in a recent placement, expanding its subscription base and preparing to capitalize on new aged care legislation set to take effect in November 2025.

Talius Group has secured $4 million through an upsized placement, reflecting strong investor confidence in its remote care platform amid regulatory shifts in aged care funding.